These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 38785918)
1. Navigating the Evolving Landscape of Primary Hyperoxaluria: Traditional Management Defied by the Rise of Novel Molecular Drugs. Huang Y; Zhu W; Zhou J; Huang Q; Zeng G Biomolecules; 2024 Apr; 14(5):. PubMed ID: 38785918 [TBL] [Abstract][Full Text] [Related]
2. Targeting kidney inflammation as a new therapy for primary hyperoxaluria? Martin-Higueras C; Ludwig-Portugall I; Hoppe B; Kurts C Nephrol Dial Transplant; 2019 Jun; 34(6):908-914. PubMed ID: 30169827 [TBL] [Abstract][Full Text] [Related]
3. Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review. Demoulin N; Aydin S; Gillion V; Morelle J; Jadoul M Am J Kidney Dis; 2022 May; 79(5):717-727. PubMed ID: 34508834 [TBL] [Abstract][Full Text] [Related]
4. Generation and characterization of a novel rat model of primary hyperoxaluria type 1 with a nonsense mutation in alanine-glyoxylate aminotransferase gene. Li Y; Zheng R; Xu G; Huang Y; Li Y; Li D; Geng H Am J Physiol Renal Physiol; 2021 Mar; 320(3):F475-F484. PubMed ID: 33491567 [TBL] [Abstract][Full Text] [Related]
5. Molecular basis of primary hyperoxaluria: clues to innovative treatments. Dindo M; Conter C; Oppici E; Ceccarelli V; Marinucci L; Cellini B Urolithiasis; 2019 Feb; 47(1):67-78. PubMed ID: 30430197 [TBL] [Abstract][Full Text] [Related]
6. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria. Lai C; Pursell N; Gierut J; Saxena U; Zhou W; Dills M; Diwanji R; Dutta C; Koser M; Nazef N; Storr R; Kim B; Martin-Higueras C; Salido E; Wang W; Abrams M; Dudek H; Brown BD Mol Ther; 2018 Aug; 26(8):1983-1995. PubMed ID: 29914758 [TBL] [Abstract][Full Text] [Related]
7. A molecular journey on the pathogenesis of primary hyperoxaluria. Cellini B Curr Opin Nephrol Hypertens; 2024 Jul; 33(4):398-404. PubMed ID: 38602143 [TBL] [Abstract][Full Text] [Related]
8. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Monico CG; Rossetti S; Belostotsky R; Cogal AG; Herges RM; Seide BM; Olson JB; Bergstrahl EJ; Williams HJ; Haley WE; Frishberg Y; Milliner DS Clin J Am Soc Nephrol; 2011 Sep; 6(9):2289-95. PubMed ID: 21896830 [TBL] [Abstract][Full Text] [Related]
9. The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria. Buchalski B; Wood KD; Challa A; Fargue S; Holmes RP; Lowther WT; Knight J Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165633. PubMed ID: 31821850 [TBL] [Abstract][Full Text] [Related]
10. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. Liebow A; Li X; Racie T; Hettinger J; Bettencourt BR; Najafian N; Haslett P; Fitzgerald K; Holmes RP; Erbe D; Querbes W; Knight J J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743 [TBL] [Abstract][Full Text] [Related]
11. Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Marangella M; Petrarulo M; Cosseddu D; Vitale C; Linari F Am J Kidney Dis; 1992 Jun; 19(6):546-53. PubMed ID: 1595703 [TBL] [Abstract][Full Text] [Related]
12. Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Scheinman JI; Voziyan PA; Belmont JM; Chetyrkin SV; Kim D; Hudson BG Urol Res; 2005 Nov; 33(5):368-71. PubMed ID: 16292584 [TBL] [Abstract][Full Text] [Related]
13. Effect of alanine supplementation on oxalate synthesis. Wood KD; Freeman BL; Killian ME; Lai WS; Assimos D; Knight J; Fargue S Biochim Biophys Acta Mol Basis Dis; 2021 Jan; 1867(1):165981. PubMed ID: 33002578 [TBL] [Abstract][Full Text] [Related]
14. Perspectives in primary hyperoxaluria - historical, current and future clinical interventions. Shee K; Stoller ML Nat Rev Urol; 2022 Mar; 19(3):137-146. PubMed ID: 34880452 [TBL] [Abstract][Full Text] [Related]
15. ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria. Ariceta G; Collard L; Abroug S; Moochhala SH; Gould E; Boussetta A; Ben Hmida M; De S; Hunley TE; Jarraya F; Fraga G; Banos A; Lindner E; Dehmel B; Schalk G Pediatr Nephrol; 2023 Feb; 38(2):403-415. PubMed ID: 35552824 [TBL] [Abstract][Full Text] [Related]
16. Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase. Li X; Knight J; Fargue S; Buchalski B; Guan Z; Inscho EW; Liebow A; Fitzgerald K; Querbes W; Todd Lowther W; Holmes RP Biochim Biophys Acta; 2016 Feb; 1862(2):233-9. PubMed ID: 26655602 [TBL] [Abstract][Full Text] [Related]